文献速递消化内镜消化道出血

结肠镜检查后血栓栓塞事件的风险:一项真实世界队列研究

Risk of Postcolonoscopy Thromboembolic Events: A Real-World Cohort Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-09-24

这项回顾性队列研究纳入2016年1月至2021年3月连续接受结肠镜检查的6220例患者,评估结肠镜检查后血栓栓塞事件的发生率及其与抗血栓药物中断的关联。结果显示结肠镜后血栓栓塞事件总体发生率低(0.32%),但中断抗血栓药物(尤其是停用两种及以上药物、氯吡格雷、华法林或直接口服抗凝药)与更高的血栓栓塞事件相关。

要点

  • 6220例结肠镜检查患者中20例(0.32%)发生血栓栓塞事件。
  • 使用双联抗血小板治疗者血栓栓塞事件率最高(4.65%,aOR 28.0)。
  • 中断抗血栓药物与结肠镜后血栓栓塞事件风险升高相关,尤其在高危患者中。

核心结论

  • 结肠镜检查后血栓栓塞事件风险低,但暂时中断抗血栓药物(尤其是停用两种及以上药物、氯吡格雷、华法林或直接口服抗凝药)与更高的结肠镜后血栓栓塞事件相关,尤其在高危患者中。

研究设计与样本

  • 回顾性队列研究,纳入2016年1月至2021年3月连续接受结肠镜检查的患者6220例,其中1755例(28.2%)使用抗血栓药物。

主要发现

  • 总体20例(0.32%)发生血栓栓塞事件,3134例息肉切除术患者中25例(0.80%)发生大出血。
  • 使用抗血栓药物者中,双联抗血小板治疗者血栓栓塞事件率4.65%(aOR 28.0,95%CI 3.77-142.1),氯吡格雷者2.78%(aOR 12.2,95%CI 2.10-57.0),未使用抗血栓药物者0.11%。
  • 中断抗血栓药物者中,停用两种及以上药物者血栓栓塞事件率4.55%(aOR 22.5,95%CI 1.09-158.0),氯吡格雷单药者3.06%(aOR 15.5,95%CI 2.86-69.6),华法林者1.33%(aOR 6.96,95%CI 1.14-33.5),直接口服抗凝药者0.87%(aOR 6.23,95%CI 1.22-26.8),均高于未使用抗血栓药物者。
  • 存在潜在高血栓栓塞风险与更高的结肠镜后血栓栓塞事件相关(aOR 16.8,95%CI 6.33-46.6)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND& AIMS: Although antithrombotic agents could increase the risk of postpolypectomy bleeding, interruption of these agents also increases the risk of thromboembolism (TE). We assessed the risks of postcolonoscopy TE events and their association with the interruption of antithrombotic agents. METHODS: This was a retrospective cohort study including consecutive patients undergoing colonoscopy between January 2016 and March 2021. We determined the rates of postcolonoscopy TE events in patients taking various antithrombotic agents (with or without interruption), and in different patient groups according to indications for colonoscopy, underlying TE, and bleeding risks. RESULTS: Of the 6220 patients, 1755 (28.2%) were on antithrombotics. Overall, 20 patients (0.32%) developed TE events, and 25 (0.80%) of 3134 patients with polypectomy experienced major episodes of bleeding. Among all patients on antithrombotic agents, the highest rates of TE events were observed in patients on dual-antiplatelet therapy (4.65%; adjusted odds ratio [aOR], 28.0; 95% CI, 3.77-142.1) and clopidogrel (2.78%; aOR, 12.2; 95% CI, 2.10-57.0), compared with 0.11% among those not on antithrombotics. In patients interrupting anti-thrombotic agents, the risk of TE was increased compared to those on no agent as follows: stopping 2 or more antithrombotic agents (4.55%; aOR, 22.5; 95% CI, 1.09-158.0), monotherapy with clopidogrel (3.06%; aOR, 15.5; 95% CI, 2.86-69.6), warfarin (1.33%; aOR, 6.96; 95% CI, 1.14-33.5), or direct-acting oral anticoagulants (0.87%; aOR, 6.23; 95% CI, 1.22-26.8). Having an underlying high TE risk (aOR, 16.8; 95% CI, 6.33-46.6) was associated with higher postcolonoscopy TE events. CONCLUSIONS: The risk of post-colonoscopy thromboembolic events is low. However, the temporary interruption of antithrombotic agents, particularly stopping 2 or more agents, clopidogrel, warfarin, or direct-acting oral anticoagulants was associated with higher postcolonoscopy TE events, particularly in high-risk patients.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Li YK, Guo CG, Cheung KS, et al. Risk of Postcolonoscopy Thromboembolic Events: A Real-World Cohort Study. Clin Gastroenterol Hepatol. 2022. PMID: 36167228. doi:10.1016/j.cgh.2022.09.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。